カテゴリー： GlobalInfoResearch, 世界, 医療/バイオ

世界の先端巨大症・巨人症治療薬市場2022年：ソマトスタチン類似体、GH受容体拮抗薬、ドーパミン作動薬、組換えヒトIGF-1

◆英語タイトル：Global Acromegaly and Gigantism Drugs Market 2022 by Manufacturers, Regions, Type and Application, Forecast to 2028
	◆商品コード：GIR22MY8715 ◆発行会社（リサーチ会社）：GlobalInfoResearch ◆発行日：2022年5月（※2025年版があります。お問い合わせください。） ◆ページ数：71 ◆レポート形式：英語 / PDF ◆納品方法：Eメール（注文後2-3日） ◆調査対象地域：グローバル ◆産業分野：医薬品

◆販売価格オプション（消費税別）

Single User（1名様閲覧用）	USD3,480 ⇒換算￥528,960	見積依頼/購入/質問フォーム
Multi User（20名様閲覧用）	USD5,220 ⇒換算￥793,440	見積依頼/購入/質問フォーム
Corporate User（同一法人内共有可）	USD6,960 ⇒換算￥1,057,920	見積依頼/購入/質問フォーム

★GlobalInfoResearchに受託調査の見積を依頼する

※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いに変更可）
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。

❖ レポートの概要 ❖

先端巨大症・巨人症治療薬市場レポートは、世界の市場規模、地域および国レベルの市場規模、セグメント市場の成長性、市場シェア、競争環境、販売分析、国内および世界の市場プレーヤーの影響、バリューチェーンの最適化、最近の動向、機会分析、市場成長の戦略的な分析、製品発売、地域市場の拡大などに関する情報を提供します。
GlobalInfoResearchの最新の調査によると、世界の先端巨大症・巨人症治療薬の市場規模は2021年のxxx米ドルから2028年にはxxx米ドルと推定され、xxx％の成長率で成長すると予想されます。

先端巨大症・巨人症治療薬市場は種類と用途によって区分されます。2017年～2028年において、量と金額の観点から種類別および用途別セグメントの売上予測データを提供します。この分析は、適格なニッチ市場をターゲットにすることでビジネスを拡大するのに役立ちます。

種類別セグメントは次をカバーします。
・ソマトスタチン類似体、GH受容体拮抗薬、ドーパミン作動薬、組換えヒトIGF-1

用途別セグメントは次のように区分されます。
・病院、クリニック、その他

世界の先端巨大症・巨人症治療薬市場の主要な市場プレーヤーは以下のとおりです。
・Ipsen、Novartis、Pfizer

地域別セグメントは次の地域・国をカバーします。
・北米（米国、カナダ、メキシコ）
・ヨーロッパ（ドイツ、フランス、イギリス、ロシア、イタリア）
・アジア太平洋（日本、中国、韓国、インド、東南アジア、オーストラリア）
・南アメリカ（ブラジル、アルゼンチン、コロンビア）
・中東およびアフリカ（サウジアラビア、UAE、エジプト、南アフリカ）

本調査レポートの内容は計15章あります。
・第1章では、先端巨大症・巨人症治療薬製品の調査範囲、市場の概要、市場の成長要因・阻害要因、および市場動向について説明します。
・第2章では、主要な先端巨大症・巨人症治療薬メーカーの企業概要、2019年～2022年までの先端巨大症・巨人症治療薬の価格、販売量、売上、市場シェアを掲載しています。
・第3章では、主要な先端巨大症・巨人症治療薬メーカーの競争状況、販売量、売上、世界市場シェアが重点的に比較分析されています。
・第4章では、2017年～2028年までの地域別先端巨大症・巨人症治療薬の販売量、売上、成長性を示しています。
・第5、6章では、2017年～2028年までの先端巨大症・巨人症治療薬の種類別と用途別の市場規模、市場シェアと成長率を掲載しています。
・第7、8、9、10、11章では、2017年～2022年までの世界の主要国での販売量、売上、市場シェア、並びに2023年～2028年までの主要地域での先端巨大症・巨人症治療薬市場予測を収録しています。
・第12章では、主要な原材料、主要なサプライヤー、および先端巨大症・巨人症治療薬の産業チェーンを掲載しています。
・第13、14、15章では、先端巨大症・巨人症治療薬の販売チャネル、販売業者、顧客、調査結果と結論、付録、データソースなどについて説明します。

***** 目次(一部) *****

・市場概要
・メーカー情報（企業概要、製品概要、販売量、価格、売上）：Ipsen、Novartis、Pfizer
・メーカー別市場シェア
・地域別市場分析2017年-2028年
・種類別分析2017年-2028年：ソマトスタチン類似体、GH受容体拮抗薬、ドーパミン作動薬、組換えヒトIGF-1
・用途別分析2017年-2028年：病院、クリニック、その他
・先端巨大症・巨人症治療薬の北米市場規模2017年-2028年：アメリカ、カナダ、メキシコ
・先端巨大症・巨人症治療薬のヨーロッパ市場規模2017年-2028年：ドイツ、イギリス、フランス、ロシア、イタリア
・先端巨大症・巨人症治療薬のアジア市場規模2017年-2028年：中国、日本、韓国、インド、東南アジア、オーストラリア
・先端巨大症・巨人症治療薬の南米市場規模2017年-2028年：ブラジル、アルゼンチン
・先端巨大症・巨人症治療薬の中東・アフリカ市場規模2017年-2028年：サウジアラビア、トルコ、エジプト、南アフリカ
・原材料および産業チェーン
・販売チャネル、流通業者・代理店、顧客リスト
・調査の結果・結論

The Acromegaly and Gigantism Drugs market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our (Global Info Research) latest study, due to COVID-19 pandemic, the global Acromegaly and Gigantism Drugs market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of USD million by 2028 with a CAGR of % during review period. Hospitals accounting for % of the Acromegaly and Gigantism Drugs global market in 2021, is projected to value USD million by 2028, growing at a % CAGR in next six years. While Somatostatin Analogs segment is altered to a % CAGR between 2022 and 2028.
Global key manufacturers of Acromegaly and Gigantism Drugs include Ipsen, Novartis, Pfizer, , and , etc. In terms of revenue, the global top four players hold a share over % in 2021.
Market segmentation
Acromegaly and Gigantism Drugs market is split by Type and by Application. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
Somatostatin Analogs
GH Receptor Antagonists
Dopamine Agonists
Recombinant Human IGF-1
Market segment by Application can be divided into
Hospitals
Clinics
Others
The key market players for global Acromegaly and Gigantism Drugs market are listed below:
Ipsen
Novartis
Pfizer
Market segment by region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Acromegaly and Gigantism Drugs product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Acromegaly and Gigantism Drugs, with price, sales, revenue and global market share of Acromegaly and Gigantism Drugs from 2019 to 2022.
Chapter 3, the Acromegaly and Gigantism Drugs competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Acromegaly and Gigantism Drugs breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2017 to 2028.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2017 to 2028.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2017 to 2022.and Acromegaly and Gigantism Drugs market forecast, by regions, type and application, with sales and revenue, from 2023 to 2028.
Chapter 12, the key raw materials and key suppliers, and industry chain of Acromegaly and Gigantism Drugs.
Chapter 13, 14, and 15, to describe Acromegaly and Gigantism Drugs sales channel, distributors, customers, research findings and conclusion, appendix and data source.

❖ レポートの目次 ❖

1 Market Overview
1.1 Acromegaly and Gigantism Drugs Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global Acromegaly and Gigantism Drugs Revenue by Type: 2017 Versus 2021 Versus 2028
1.2.2 Somatostatin Analogs
1.2.3 GH Receptor Antagonists
1.2.4 Dopamine Agonists
1.2.5 Recombinant Human IGF-1
1.3 Market Analysis by Application
1.3.1 Overview: Global Acromegaly and Gigantism Drugs Revenue by Application: 2017 Versus 2021 Versus 2028
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Others
1.4 Global Acromegaly and Gigantism Drugs Market Size & Forecast
1.4.1 Global Acromegaly and Gigantism Drugs Sales in Value (2017 & 2021 & 2028)
1.4.2 Global Acromegaly and Gigantism Drugs Sales in Volume (2017-2028)
1.4.3 Global Acromegaly and Gigantism Drugs Price (2017-2028)
1.5 Global Acromegaly and Gigantism Drugs Production Capacity Analysis
1.5.1 Global Acromegaly and Gigantism Drugs Total Production Capacity (2017-2028)
1.5.2 Global Acromegaly and Gigantism Drugs Production Capacity by Geographic Region
1.6 Market Drivers, Restraints and Trends
1.6.1 Acromegaly and Gigantism Drugs Market Drivers
1.6.2 Acromegaly and Gigantism Drugs Market Restraints
1.6.3 Acromegaly and Gigantism Drugs Trends Analysis
2 Manufacturers Profiles
2.1 Ipsen
2.1.1 Ipsen Details
2.1.2 Ipsen Major Business
2.1.3 Ipsen Acromegaly and Gigantism Drugs Product and Services
2.1.4 Ipsen Acromegaly and Gigantism Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.2 Novartis
2.2.1 Novartis Details
2.2.2 Novartis Major Business
2.2.3 Novartis Acromegaly and Gigantism Drugs Product and Services
2.2.4 Novartis Acromegaly and Gigantism Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.3 Pfizer
2.3.1 Pfizer Details
2.3.2 Pfizer Major Business
2.3.3 Pfizer Acromegaly and Gigantism Drugs Product and Services
2.3.4 Pfizer Acromegaly and Gigantism Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
3 Acromegaly and Gigantism Drugs Breakdown Data by Manufacturer
3.1 Global Acromegaly and Gigantism Drugs Sales in Volume by Manufacturer (2019, 2020, 2021, and 2022)
3.2 Global Acromegaly and Gigantism Drugs Revenue by Manufacturer (2019, 2020, 2021, and 2022)
3.3 Key Manufacturer Market Position in Acromegaly and Gigantism Drugs
3.4 Market Concentration Rate
3.4.1 Top 3 Acromegaly and Gigantism Drugs Manufacturer Market Share in 2021
3.4.2 Top 6 Acromegaly and Gigantism Drugs Manufacturer Market Share in 2021
3.5 Global Acromegaly and Gigantism Drugs Production Capacity by Company: 2021 VS 2022
3.6 Manufacturer by Geography: Head Office and Acromegaly and Gigantism Drugs Production Site
3.7 New Entrant and Capacity Expansion Plans
3.8 Mergers & Acquisitions
4 Market Analysis by Region
4.1 Global Acromegaly and Gigantism Drugs Market Size by Region
4.1.1 Global Acromegaly and Gigantism Drugs Sales in Volume by Region (2017-2028)
4.1.2 Global Acromegaly and Gigantism Drugs Revenue by Region (2017-2028)
4.2 North America Acromegaly and Gigantism Drugs Revenue (2017-2028)
4.3 Europe Acromegaly and Gigantism Drugs Revenue (2017-2028)
4.4 Asia-Pacific Acromegaly and Gigantism Drugs Revenue (2017-2028)
4.5 South America Acromegaly and Gigantism Drugs Revenue (2017-2028)
4.6 Middle East and Africa Acromegaly and Gigantism Drugs Revenue (2017-2028)
5 Market Segment by Type
5.1 Global Acromegaly and Gigantism Drugs Sales in Volume by Type (2017-2028)
5.2 Global Acromegaly and Gigantism Drugs Revenue by Type (2017-2028)
5.3 Global Acromegaly and Gigantism Drugs Price by Type (2017-2028)
6 Market Segment by Application
6.1 Global Acromegaly and Gigantism Drugs Sales in Volume by Application (2017-2028)
6.2 Global Acromegaly and Gigantism Drugs Revenue by Application (2017-2028)
6.3 Global Acromegaly and Gigantism Drugs Price by Application (2017-2028)
7 North America by Country, by Type, and by Application
7.1 North America Acromegaly and Gigantism Drugs Sales by Type (2017-2028)
7.2 North America Acromegaly and Gigantism Drugs Sales by Application (2017-2028)
7.3 North America Acromegaly and Gigantism Drugs Market Size by Country
7.3.1 North America Acromegaly and Gigantism Drugs Sales in Volume by Country (2017-2028)
7.3.2 North America Acromegaly and Gigantism Drugs Revenue by Country (2017-2028)
7.3.3 United States Market Size and Forecast (2017-2028)
7.3.4 Canada Market Size and Forecast (2017-2028)
7.3.5 Mexico Market Size and Forecast (2017-2028)
8 Europe by Country, by Type, and by Application
8.1 Europe Acromegaly and Gigantism Drugs Sales by Type (2017-2028)
8.2 Europe Acromegaly and Gigantism Drugs Sales by Application (2017-2028)
8.3 Europe Acromegaly and Gigantism Drugs Market Size by Country
8.3.1 Europe Acromegaly and Gigantism Drugs Sales in Volume by Country (2017-2028)
8.3.2 Europe Acromegaly and Gigantism Drugs Revenue by Country (2017-2028)
8.3.3 Germany Market Size and Forecast (2017-2028)
8.3.4 France Market Size and Forecast (2017-2028)
8.3.5 United Kingdom Market Size and Forecast (2017-2028)
8.3.6 Russia Market Size and Forecast (2017-2028)
8.3.7 Italy Market Size and Forecast (2017-2028)
9 Asia-Pacific by Region, by Type, and by Application
9.1 Asia-Pacific Acromegaly and Gigantism Drugs Sales by Type (2017-2028)
9.2 Asia-Pacific Acromegaly and Gigantism Drugs Sales by Application (2017-2028)
9.3 Asia-Pacific Acromegaly and Gigantism Drugs Market Size by Region
9.3.1 Asia-Pacific Acromegaly and Gigantism Drugs Sales in Volume by Region (2017-2028)
9.3.2 Asia-Pacific Acromegaly and Gigantism Drugs Revenue by Region (2017-2028)
9.3.3 China Market Size and Forecast (2017-2028)
9.3.4 Japan Market Size and Forecast (2017-2028)
9.3.5 Korea Market Size and Forecast (2017-2028)
9.3.6 India Market Size and Forecast (2017-2028)
9.3.7 Southeast Asia Market Size and Forecast (2017-2028)
9.3.8 Australia Market Size and Forecast (2017-2028)
10 South America by Region, by Type, and by Application
10.1 South America Acromegaly and Gigantism Drugs Sales by Type (2017-2028)
10.2 South America Acromegaly and Gigantism Drugs Sales by Application (2017-2028)
10.3 South America Acromegaly and Gigantism Drugs Market Size by Country
10.3.1 South America Acromegaly and Gigantism Drugs Sales in Volume by Country (2017-2028)
10.3.2 South America Acromegaly and Gigantism Drugs Revenue by Country (2017-2028)
10.3.3 Brazil Market Size and Forecast (2017-2028)
10.3.4 Argentina Market Size and Forecast (2017-2028)
11 Middle East & Africa by Country, by Type, and by Application
11.1 Middle East & Africa Acromegaly and Gigantism Drugs Sales by Type (2017-2028)
11.2 Middle East & Africa Acromegaly and Gigantism Drugs Sales by Application (2017-2028)
11.3 Middle East & Africa Acromegaly and Gigantism Drugs Market Size by Country
11.3.1 Middle East & Africa Acromegaly and Gigantism Drugs Sales in Volume by Country (2017-2028)
11.3.2 Middle East & Africa Acromegaly and Gigantism Drugs Revenue by Country (2017-2028)
11.3.3 Turkey Market Size and Forecast (2017-2028)
11.3.4 Egypt Market Size and Forecast (2017-2028)
11.3.5 Saudi Arabia Market Size and Forecast (2017-2028)
11.3.6 South Africa Market Size and Forecast (2017-2028)
12 Raw Material and Industry Chain
12.1 Raw Material of Acromegaly and Gigantism Drugs and Key Manufacturers
12.2 Manufacturing Costs Percentage of Acromegaly and Gigantism Drugs
12.3 Acromegaly and Gigantism Drugs Production Process
12.4 Acromegaly and Gigantism Drugs Industrial Chain
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.2 Acromegaly and Gigantism Drugs Typical Distributors
13.3 Acromegaly and Gigantism Drugs Typical Customers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Research Process and Data Source
15.3 Disclaimer

List of Tables
Table 1. Global Acromegaly and Gigantism Drugs Revenue by Type, (USD Million), 2017 & 2021 & 2028
Table 2. Global Acromegaly and Gigantism Drugs Revenue by Application, (USD Million), 2017 & 2021 & 2028
Table 3. Ipsen Basic Information, Manufacturing Base and Competitors
Table 4. Ipsen Major Business
Table 5. Ipsen Acromegaly and Gigantism Drugs Product and Services
Table 6. Ipsen Acromegaly and Gigantism Drugs Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 7. Novartis Basic Information, Manufacturing Base and Competitors
Table 8. Novartis Major Business
Table 9. Novartis Acromegaly and Gigantism Drugs Product and Services
Table 10. Novartis Acromegaly and Gigantism Drugs Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 11. Pfizer Basic Information, Manufacturing Base and Competitors
Table 12. Pfizer Major Business
Table 13. Pfizer Acromegaly and Gigantism Drugs Product and Services
Table 14. Pfizer Acromegaly and Gigantism Drugs Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 15. Global Acromegaly and Gigantism Drugs Sales by Manufacturer (2019, 2020, 2021, and 2022) & (K Units)
Table 16. Global Acromegaly and Gigantism Drugs Revenue by Manufacturer (2019, 2020, 2021, and 2022) & (USD Million)
Table 17. Market Position of Manufacturers in Acromegaly and Gigantism Drugs, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2021
Table 18. Global Acromegaly and Gigantism Drugs Production Capacity by Company, (K Units): 2020 VS 2021
Table 19. Head Office and Acromegaly and Gigantism Drugs Production Site of Key Manufacturer
Table 20. Acromegaly and Gigantism Drugs New Entrant and Capacity Expansion Plans
Table 21. Acromegaly and Gigantism Drugs Mergers & Acquisitions in the Past Five Years
Table 22. Global Acromegaly and Gigantism Drugs Sales by Region (2017-2022) & (K Units)
Table 23. Global Acromegaly and Gigantism Drugs Sales by Region (2023-2028) & (K Units)
Table 24. Global Acromegaly and Gigantism Drugs Revenue by Region (2017-2022) & (USD Million)
Table 25. Global Acromegaly and Gigantism Drugs Revenue by Region (2023-2028) & (USD Million)
Table 26. Global Acromegaly and Gigantism Drugs Sales by Type (2017-2022) & (K Units)
Table 27. Global Acromegaly and Gigantism Drugs Sales by Type (2023-2028) & (K Units)
Table 28. Global Acromegaly and Gigantism Drugs Revenue by Type (2017-2022) & (USD Million)
Table 29. Global Acromegaly and Gigantism Drugs Revenue by Type (2023-2028) & (USD Million)
Table 30. Global Acromegaly and Gigantism Drugs Price by Type (2017-2022) & (USD/Unit)
Table 31. Global Acromegaly and Gigantism Drugs Price by Type (2023-2028) & (USD/Unit)
Table 32. Global Acromegaly and Gigantism Drugs Sales by Application (2017-2022) & (K Units)
Table 33. Global Acromegaly and Gigantism Drugs Sales by Application (2023-2028) & (K Units)
Table 34. Global Acromegaly and Gigantism Drugs Revenue by Application (2017-2022) & (USD Million)
Table 35. Global Acromegaly and Gigantism Drugs Revenue by Application (2023-2028) & (USD Million)
Table 36. Global Acromegaly and Gigantism Drugs Price by Application (2017-2022) & (USD/Unit)
Table 37. Global Acromegaly and Gigantism Drugs Price by Application (2023-2028) & (USD/Unit)
Table 38. North America Acromegaly and Gigantism Drugs Sales by Country (2017-2022) & (K Units)
Table 39. North America Acromegaly and Gigantism Drugs Sales by Country (2023-2028) & (K Units)
Table 40. North America Acromegaly and Gigantism Drugs Revenue by Country (2017-2022) & (USD Million)
Table 41. North America Acromegaly and Gigantism Drugs Revenue by Country (2023-2028) & (USD Million)
Table 42. North America Acromegaly and Gigantism Drugs Sales by Type (2017-2022) & (K Units)
Table 43. North America Acromegaly and Gigantism Drugs Sales by Type (2023-2028) & (K Units)
Table 44. North America Acromegaly and Gigantism Drugs Sales by Application (2017-2022) & (K Units)
Table 45. North America Acromegaly and Gigantism Drugs Sales by Application (2023-2028) & (K Units)
Table 46. Europe Acromegaly and Gigantism Drugs Sales by Country (2017-2022) & (K Units)
Table 47. Europe Acromegaly and Gigantism Drugs Sales by Country (2023-2028) & (K Units)
Table 48. Europe Acromegaly and Gigantism Drugs Revenue by Country (2017-2022) & (USD Million)
Table 49. Europe Acromegaly and Gigantism Drugs Revenue by Country (2023-2028) & (USD Million)
Table 50. Europe Acromegaly and Gigantism Drugs Sales by Type (2017-2022) & (K Units)
Table 51. Europe Acromegaly and Gigantism Drugs Sales by Type (2023-2028) & (K Units)
Table 52. Europe Acromegaly and Gigantism Drugs Sales by Application (2017-2022) & (K Units)
Table 53. Europe Acromegaly and Gigantism Drugs Sales by Application (2023-2028) & (K Units)
Table 54. Asia-Pacific Acromegaly and Gigantism Drugs Sales by Region (2017-2022) & (K Units)
Table 55. Asia-Pacific Acromegaly and Gigantism Drugs Sales by Region (2023-2028) & (K Units)
Table 56. Asia-Pacific Acromegaly and Gigantism Drugs Revenue by Region (2017-2022) & (USD Million)
Table 57. Asia-Pacific Acromegaly and Gigantism Drugs Revenue by Region (2023-2028) & (USD Million)
Table 58. Asia-Pacific Acromegaly and Gigantism Drugs Sales by Type (2017-2022) & (K Units)
Table 59. Asia-Pacific Acromegaly and Gigantism Drugs Sales by Type (2023-2028) & (K Units)
Table 60. Asia-Pacific Acromegaly and Gigantism Drugs Sales by Application (2017-2022) & (K Units)
Table 61. Asia-Pacific Acromegaly and Gigantism Drugs Sales by Application (2023-2028) & (K Units)
Table 62. South America Acromegaly and Gigantism Drugs Sales by Country (2017-2022) & (K Units)
Table 63. South America Acromegaly and Gigantism Drugs Sales by Country (2023-2028) & (K Units)
Table 64. South America Acromegaly and Gigantism Drugs Revenue by Country (2017-2022) & (USD Million)
Table 65. South America Acromegaly and Gigantism Drugs Revenue by Country (2023-2028) & (USD Million)
Table 66. South America Acromegaly and Gigantism Drugs Sales by Type (2017-2022) & (K Units)
Table 67. South America Acromegaly and Gigantism Drugs Sales by Type (2023-2028) & (K Units)
Table 68. South America Acromegaly and Gigantism Drugs Sales by Application (2017-2022) & (K Units)
Table 69. South America Acromegaly and Gigantism Drugs Sales by Application (2023-2028) & (K Units)
Table 70. Middle East & Africa Acromegaly and Gigantism Drugs Sales by Region (2017-2022) & (K Units)
Table 71. Middle East & Africa Acromegaly and Gigantism Drugs Sales by Region (2023-2028) & (K Units)
Table 72. Middle East & Africa Acromegaly and Gigantism Drugs Revenue by Region (2017-2022) & (USD Million)
Table 73. Middle East & Africa Acromegaly and Gigantism Drugs Revenue by Region (2023-2028) & (USD Million)
Table 74. Middle East & Africa Acromegaly and Gigantism Drugs Sales by Type (2017-2022) & (K Units)
Table 75. Middle East & Africa Acromegaly and Gigantism Drugs Sales by Type (2023-2028) & (K Units)
Table 76. Middle East & Africa Acromegaly and Gigantism Drugs Sales by Application (2017-2022) & (K Units)
Table 77. Middle East & Africa Acromegaly and Gigantism Drugs Sales by Application (2023-2028) & (K Units)
Table 78. Acromegaly and Gigantism Drugs Raw Material
Table 79. Key Manufacturers of Acromegaly and Gigantism Drugs Raw Materials
Table 80. Direct Channel Pros & Cons
Table 81. Indirect Channel Pros & Cons
Table 82. Acromegaly and Gigantism Drugs Typical Distributors
Table 83. Acromegaly and Gigantism Drugs Typical Customers
List of Figures
Figure 1. Acromegaly and Gigantism Drugs Picture
Figure 2. Global Acromegaly and Gigantism Drugs Revenue Market Share by Type in 2021
Figure 3. Somatostatin Analogs
Figure 4. GH Receptor Antagonists
Figure 5. Dopamine Agonists
Figure 6. Recombinant Human IGF-1
Figure 7. Global Acromegaly and Gigantism Drugs Revenue Market Share by Application in 2021
Figure 8. Hospitals
Figure 9. Clinics
Figure 10. Others
Figure 11. Global Acromegaly and Gigantism Drugs Revenue, (USD Million) & (K Units): 2017 & 2021 & 2028
Figure 12. Global Acromegaly and Gigantism Drugs Revenue and Forecast (2017-2028) & (USD Million)
Figure 13. Global Acromegaly and Gigantism Drugs Sales (2017-2028) & (K Units)
Figure 14. Global Acromegaly and Gigantism Drugs Price (2017-2028) & (USD/Unit)
Figure 15. Global Acromegaly and Gigantism Drugs Production Capacity (2017-2028) & (K Units)
Figure 16. Global Acromegaly and Gigantism Drugs Production Capacity by Geographic Region: 2022 VS 2028
Figure 17. Acromegaly and Gigantism Drugs Market Drivers
Figure 18. Acromegaly and Gigantism Drugs Market Restraints
Figure 19. Acromegaly and Gigantism Drugs Market Trends
Figure 20. Global Acromegaly and Gigantism Drugs Sales Market Share by Manufacturer in 2021
Figure 21. Global Acromegaly and Gigantism Drugs Revenue Market Share by Manufacturer in 2021
Figure 22. Acromegaly and Gigantism Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3) in 2021
Figure 23. Top 3 Acromegaly and Gigantism Drugs Manufacturer (Revenue) Market Share in 2021
Figure 24. Top 6 Acromegaly and Gigantism Drugs Manufacturer (Revenue) Market Share in 2021
Figure 25. Global Acromegaly and Gigantism Drugs Sales Market Share by Region (2017-2028)
Figure 26. Global Acromegaly and Gigantism Drugs Revenue Market Share by Region (2017-2028)
Figure 27. North America Acromegaly and Gigantism Drugs Revenue (2017-2028) & (USD Million)
Figure 28. Europe Acromegaly and Gigantism Drugs Revenue (2017-2028) & (USD Million)
Figure 29. Asia-Pacific Acromegaly and Gigantism Drugs Revenue (2017-2028) & (USD Million)
Figure 30. South America Acromegaly and Gigantism Drugs Revenue (2017-2028) & (USD Million)
Figure 31. Middle East & Africa Acromegaly and Gigantism Drugs Revenue (2017-2028) & (USD Million)
Figure 32. Global Acromegaly and Gigantism Drugs Sales Market Share by Type (2017-2028)
Figure 33. Global Acromegaly and Gigantism Drugs Revenue Market Share by Type (2017-2028)
Figure 34. Global Acromegaly and Gigantism Drugs Price by Type (2017-2028) & (USD/Unit)
Figure 35. Global Acromegaly and Gigantism Drugs Sales Market Share by Application (2017-2028)
Figure 36. Global Acromegaly and Gigantism Drugs Revenue Market Share by Application (2017-2028)
Figure 37. Global Acromegaly and Gigantism Drugs Price by Application (2017-2028) & (USD/Unit)
Figure 38. North America Acromegaly and Gigantism Drugs Sales Market Share by Type (2017-2028)
Figure 39. North America Acromegaly and Gigantism Drugs Sales Market Share by Application (2017-2028)
Figure 40. North America Acromegaly and Gigantism Drugs Sales Market Share by Country (2017-2028)
Figure 41. North America Acromegaly and Gigantism Drugs Revenue Market Share by Country (2017-2028)
Figure 42. United States Acromegaly and Gigantism Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 43. Canada Acromegaly and Gigantism Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 44. Mexico Acromegaly and Gigantism Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 45. Europe Acromegaly and Gigantism Drugs Sales Market Share by Type (2017-2028)
Figure 46. Europe Acromegaly and Gigantism Drugs Sales Market Share by Application (2017-2028)
Figure 47. Europe Acromegaly and Gigantism Drugs Sales Market Share by Country (2017-2028)
Figure 48. Europe Acromegaly and Gigantism Drugs Revenue Market Share by Country (2017-2028)
Figure 49. Germany Acromegaly and Gigantism Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 50. France Acromegaly and Gigantism Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 51. United Kingdom Acromegaly and Gigantism Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 52. Russia Acromegaly and Gigantism Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 53. Italy Acromegaly and Gigantism Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 54. Asia-Pacific Acromegaly and Gigantism Drugs Sales Market Share by Region (2017-2028)
Figure 55. Asia-Pacific Acromegaly and Gigantism Drugs Sales Market Share by Application (2017-2028)
Figure 56. Asia-Pacific Acromegaly and Gigantism Drugs Sales Market Share by Region (2017-2028)
Figure 57. Asia-Pacific Acromegaly and Gigantism Drugs Revenue Market Share by Region (2017-2028)
Figure 58. China Acromegaly and Gigantism Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 59. Japan Acromegaly and Gigantism Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 60. Korea Acromegaly and Gigantism Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 61. India Acromegaly and Gigantism Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 62. Southeast Asia Acromegaly and Gigantism Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 63. Australia Acromegaly and Gigantism Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 64. South America Acromegaly and Gigantism Drugs Sales Market Share by Type (2017-2028)
Figure 65. South America Acromegaly and Gigantism Drugs Sales Market Share by Application (2017-2028)
Figure 66. South America Acromegaly and Gigantism Drugs Sales Market Share by Country (2017-2028)
Figure 67. South America Acromegaly and Gigantism Drugs Revenue Market Share by Country (2017-2028)
Figure 68. Brazil Acromegaly and Gigantism Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 69. Argentina Acromegaly and Gigantism Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 70. Middle East & Africa Acromegaly and Gigantism Drugs Sales Market Share by Type (2017-2028)
Figure 71. Middle East & Africa Acromegaly and Gigantism Drugs Sales Market Share by Application (2017-2028)
Figure 72. Middle East & Africa Acromegaly and Gigantism Drugs Sales Market Share by Region (2017-2028)
Figure 73. Middle East & Africa Acromegaly and Gigantism Drugs Revenue Market Share by Region (2017-2028)
Figure 74. Turkey Acromegaly and Gigantism Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 75. Egypt Acromegaly and Gigantism Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 76. Saudi Arabia Acromegaly and Gigantism Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 77. South Africa Acromegaly and Gigantism Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 78. Manufacturing Cost Structure Analysis of Acromegaly and Gigantism Drugs in 2021
Figure 79. Manufacturing Process Analysis of Acromegaly and Gigantism Drugs
Figure 80. Acromegaly and Gigantism Drugs Industrial Chain
Figure 81. Sales Channel: Direct Channel vs Indirect Channel
Figure 82. Methodology
Figure 83. Research Process and Data Source

❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 世界の先端巨大症・巨人症治療薬市場2022年：ソマトスタチン類似体、GH受容体拮抗薬、ドーパミン作動薬、組換えヒトIGF-1(Global Acromegaly and Gigantism Drugs Market 2022 by Manufacturers, Regions, Type and Application, Forecast to 2028)]についてメールでお問い合わせはこちらでお願いします。

GlobalResearch.jp

世界の先端巨大症・巨人症治療薬市場2022年：ソマトスタチン類似体、GH受容体拮抗薬、ドーパミン作動薬、組換えヒトIGF-1

グローバル市場調査/マーケットリサーチ会社：レポート販売と委託調査サービス提供 www.GlobalResearch.jp